Close Menu

NEW YORK (GenomeWeb) – Precipio is out of compliance with a Nasdaq listing requirement, the firm said in a document filed Friday with the US Securities and Exchange Commission.

The company said Nasdaq notified it on March 26 that for the past 30 consecutive business days, the closing bid price per share of its common stock was below the $1 minimum needed for continued listing.

Nasdaq has given Precipio a grace period until Sept. 24, 2018 to regain compliance by ensuring that its common stock price meets or exceeds $1 per share for at least 10 consecutive business days.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Apr
29
Sponsored by
Co-Diagnostics

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

May
13
Sponsored by
LGC SeraCare Life Sciences

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.

May
18
Sponsored by
Bio-Rad

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.